- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Mark Fendrick Testifying on Impact of VBID on TRICARE
The American Journal of Managed Care's co-editor-in-chief A. Mark Fendrick, MD, director of the University of Michigan Center for Value-Based Insurance Design (VBID), is testifying on how the principles of VBID and clinical nuance can contribute to healthcare reform in the US military health system.
On Tuesday, February 23, The American Journal of Managed Care's co-editor-in-chief A. Mark Fendrick, MD, director of the University of Michigan Center for Value-Based Insurance Design (VBID), is testifying before the United States Senate Committee on Armed Services Subcommittee on Personnel to discuss how the principles of VBID and clinical nuance can contribute to defense healthcare reform.
TRICARE, a healthcare program of the United States Department of Defense Military Health System, like most US health plans, implements cost sharing in a "one-size-fits-all" way instead of utilizing a "smarter" cost sharing solution that encourages TRICARE members to use services that make them healthier by implementing lower cost sharing, and discouraging the use of services that do not make members healthier through the use of higher cost sharing.
The use of clinically nuance variation in cost sharing gives TRICARE plans a way to encourage members to use high-value services.
Below is an infographic from the VBID Center on the impact of VBID and clinical nuance on TRICARE:
Unmet Needs Remain in Secondary AML Following Treatment With HMAs
January 18th 2025The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Read More
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
